Optimizing Genetic Testing AIM Specialty Health Integration for Efficient Prior Authorizations

The Clinical Reality of Genetic Testing Prior Authorizations with AIM Specialty Health

Genetic testing encompasses a wide range of services, from hereditary cancer panels (e.g., BRCA, Lynch syndrome) to prenatal genetic screening and pharmacogenomic testing. These high-cost, high-value services frequently trigger prior authorization requirements, often routed through specialty benefit managers like AIM. The clinical documentation required is extensive, including detailed genetic counseling notes, family history, specific gene panel justification, and sometimes patient consent forms, all of which must align with AIM's specific clinical criteria.

Common Genetic Testing PA Triggers Requiring AIM Specialty Health Approval

• Multi-gene hereditary cancer panels (e.g., breast, ovarian, colorectal cancer panels)
• Specific single-gene tests for rare genetic conditions or targeted therapies
• Non-invasive prenatal testing (NIPT) and other prenatal genetic screens
• Pharmacogenomic testing when linked to high-cost specialty drug prescriptions
• Genetic counseling services when billed separately or as part of a testing package
• Repeat genetic testing or expanded panels based on evolving clinical guidelines

EMR and Payer Touchpoints in Genetic Testing Workflows

Effective genetic testing AIM Specialty Health integration demands seamless data flow between the EMR and the payer's delegated RBM. This involves extracting patient demographics, clinical notes, genetic counseling reports, specific test order details (CPT codes, ICD-10 codes), and supporting documentation directly from the EMR. Klivira's platform automates this data extraction, mapping it to the specific fields required by AIM, whether submitted via X12 278 ePA transactions, direct API integrations, or through AIM's provider portal via Robotic Process Automation (RPA) where APIs are not available. This mitigates manual data entry errors and accelerates submission.

Leveraging Clinical Guidelines for AIM Specialty Health Submissions

Prior authorizations for genetic testing are heavily informed by established clinical guidelines. Klivira's intelligent automation platform incorporates the latest criteria from bodies such as the National Comprehensive Cancer Network (NCCN) for oncology-related panels, the American Society of Clinical Oncology (ASCO), and the American College of Medical Genetics and Genomics (ACMG). By cross-referencing patient data against these guidelines and AIM's specific medical policies, Klivira helps ensure that submissions are clinically robust and complete, reducing the likelihood of denials due to insufficient documentation or lack of medical necessity.

Klivira's Impact on Genetic Testing PA Efficiency

Implementing Klivira for genetic testing AIM Specialty Health integration transforms a labor-intensive process into an automated, high-throughput workflow. Our platform intelligently identifies PA requirements, extracts relevant clinical data from EMRs, and populates AIM's submission channels with precision. This not only reduces the administrative burden on prior authorization coordinators but also significantly decreases turnaround times for approvals, allowing patients to access critical genetic testing services without unnecessary delays. This operational efficiency directly translates to improved revenue cycle performance and patient satisfaction.